Program
Oxaliplatin
Also written as “oxaliplatin”, “Oxaliplatin (SR96669)” and “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”.
Its studies are mostly in Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Rectal Neoplasms · Carcinoma, Hepatocellular, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 360 open or running | phase 4since Aug 10, 2005 | Jan 6, 2001 | none ahead |
| Hoffmann-La Roche | 201 open or running | phase 4since Dec 18, 2007 | Sep 15, 2003 | Mar 22, 2027phase 1 · NCT06624085 |
| Prologue Research International | 30 open or running | phase 3since Jun 5, 2003 | May 6, 2001 | none ahead |
| Pfizer | 21 open or running | phase 3since Oct 5, 2020 | Nov 6, 2007 | none ahead |
| criterium-inc | 10 open or running | phase 2since Sep 24, 2019 | Sep 24, 2019 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 1since Sep 27, 2007 | Sep 27, 2007 | none ahead |
| nang-kuang-pharmaceutical-co-ltd | 10 open or running | phase 2since Mar 28, 2011 | Mar 28, 2011 | none ahead |
| NovoCure | 10 open or running | no phasesince Feb 20, 2020 | Feb 20, 2020 | none ahead |
| sirtex-medical | 10 open or running | phase 3since Aug 13, 2008 | Aug 13, 2008 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, parexel, Halozyme Therapeutics, biolinerx-ltd, AbbVie, Zai Lab, Amgen, Bristol-Myers Squibb, Regeneron Pharmaceuticals and yakult-honsha-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Sep 15, 2003.
- Jul 7, 2010Phase 2 study in Colorectal NeoplasmsHoffmann-La Roche · NCT01159171 · 50 enrolled · Italy
- Nov 19, 2010Phase 3 study in Carcinoma, HepatocellularSanofi · NCT01245582
- Mar 28, 2011nang-kuang-pharmaceutical-co-ltd's first study: phase 2 study in Head and Neck NeoplasmsNew to nang-kuang-pharmaceutical-co-ltdnang-kuang-pharmaceutical-co-ltd · NCT01370876 · 46 enrolled · Taiwan
- Jan 10, 2012Phase 3 study in Stomach NeoplasmsSanofi · NCT01515748 · 530 enrolled · Korea, Republic of
- Dec 10, 2012Phase 2 study in Stomach NeoplasmsHoffmann-La Roche · NCT01748773 · 34 enrolled · Turkey
- Sep 13, 2013Phase 2 study in Colorectal Cancer MetastaticSanofi · NCT01955629 · 4 enrolled · Italy
- May 15, 2014Phase 2 study in Colorectal NeoplasmsHoffmann-La Roche · NCT02141295 · 197 enrolled · United States, Australia, Austria and more
- Sep 24, 2015Phase 3 study in Stomach NeoplasmsHoffmann-La Roche · NCT02560974 · 1,035 enrolled · China, Korea, Republic of, Taiwan
- Feb 25, 2016Phase 2 study in Rectal NeoplasmsHoffmann-La Roche · NCT02694718 · 60 enrolled · Switzerland
- Sep 11, 2017Phase 2 study in Esophageal NeoplasmsHoffmann-La Roche · NCT03281369 · 219 enrolled · United States, Australia, Israel and more
- Sep 24, 2019criterium-inc's first study: phase 2 study in Colorectal Cancer MetastaticNew to criterium-inccriterium-inc · NCT04169347 · 27 enrolled · United States
- Feb 20, 2020NovoCure's first study: no phase study in Stomach NeoplasmsNew to NovoCureNovoCure · NCT04281576 · 28 enrolled · Hong Kong
- Oct 5, 2020Phase 3 study in NeoplasmsPfizer · NCT04607421 · 841 enrolled · United States, Argentina, Australia and more
- Oct 1, 2024Phase 1 study in LymphomaHoffmann-La Roche · NCT06624085 · 50 enrolled · United States, Puerto Rico
Ahead
- Mar 22, 2027Primary completion: phase 1 study in LymphomaHoffmann-La Roche · NCT06624085
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The newest 60 of 66 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06624085Lymphoma · United States, Puerto Rico | 1 | Active, not recruiting | Hoffmann-La Roche | Mar 22, 2027 | 50 |
| NCT04607421Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Mar 1, 2025 | 841 |
| NCT04281576Stomach Neoplasms · Hong Kong | – | Completed | NovoCure | Jun 7, 2024 | 28 |
| NCT04169347Colorectal Cancer Metastatic · United States | 2 | UNKNOWN | criterium-inc | Dec 2024 | 27 |
| NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more | 2 | Terminated | Hoffmann-La Roche | Oct 9, 2025 | 219 |
| NCT02694718Rectal Neoplasms · Switzerland | 2 | Completed | Hoffmann-La Roche | Aug 2006 | 60 |
| NCT02560974Stomach Neoplasms · China, Korea, Republic of, Taiwan | 3 | Completed | Hoffmann-La Roche | Nov 2012 | 1,035 |
| NCT02141295Colorectal Neoplasms · United States, Australia, Austria and more | 2 | Terminated | Hoffmann-La Roche | Jul 29, 2016 | 197 |
| NCT01955629Colorectal Cancer Metastatic · Italy | 2 | Terminated | Sanofi | Mar 2015 | 4 |
| NCT01748773Stomach Neoplasms · Turkey | 2 | Completed | Hoffmann-La Roche | Aug 21, 2015 | 34 |
| NCT01515748Stomach Neoplasms · Korea, Republic of | 3 | Completed | Sanofi | Jan 21, 2019 | 530 |
| NCT01370876Head and Neck Neoplasms · Taiwan | 2 | Terminated | nang-kuang-pharmaceutical-co-ltd | Aug 2011 | 46 |
| NCT01245582Carcinoma, Hepatocellular | 3 | Withdrawn | Sanofi | Feb 2014 | 0 |
| NCT01159171Colorectal Neoplasms · Italy | 2 | Completed | Hoffmann-La Roche | Jul 2010 | 50 |
| NCT01135498Colorectal Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Apr 2010 | 90 |
| NCT01130337Stomach Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Jun 2014 | 36 |
| NCT01121848Pancreatic Neoplasms · Canada | 3 | Completed | Sanofi | Oct 2013 | 108 |
| NCT01077739Colorectal Neoplasms · Belgium | 2 | Completed | Hoffmann-La Roche | Jan 2012 | 75 |
| NCT00988897Colorectal Neoplasms · Canada | 2 | Withdrawn | Sanofi | May 2012 | 0 |
| NCT00816543Stomach Neoplasms · Korea, Republic of | 2 | Completed | Sanofi | May 2012 | 41 |
| NCT00782041Uterine Neoplasms · Thailand | 2 | Terminated | Sanofi | Aug 2003 | 11 |
| NCT00735241Colorectal Neoplasms · United States | 3 | Withdrawn | sirtex-medical | Mar 2009 | 0 |
| NCT00700570Colorectal Neoplasms · Taiwan | 2 | Completed | Hoffmann-La Roche | Nov 2011 | 45 |
| NCT00642603Colorectal Neoplasms · United States | 2 | Terminated | Hoffmann-La Roche | Mar 2009 | 41 |
| NCT00623805Colorectal Neoplasms · Turkey | 3 | Completed | Hoffmann-La Roche | May 2012 | 123 |
| NCT00612495Endometrial Neoplasms · France | 2 | Completed | Sanofi | 31 | |
| NCT00611962Neoplasms, Germ Cell and Embryonal · France | 2 | Completed | Sanofi | 27 | |
| NCT00611754Head and Neck Neoplasms · France | 2 | Completed | Sanofi | 15 | |
| NCT00611507Stomach Neoplasms · Colombia | 2 | Completed | Sanofi | 21 | |
| NCT00577031Colorectal Neoplasms · Italy | 4 | Completed | Hoffmann-La Roche | Aug 2011 | 205 |
| NCT00559455Carcinoma, Hepatocellular · Korea, Republic of | 2 | Completed | Sanofi | Jan 2010 | 38 |
| NCT00555620Stomach Neoplasms · Korea, Republic of | 1 | Completed | Pfizer | Aug 2010 | 76 |
| NCT00536809Colorectal Neoplasms · United States | 1 | Completed | GlaxoSmithKline | Oct 31, 2008 | 12 |
| NCT00499850Adenocarcinoma · Australia | 1 | Completed | Sanofi | Jun 2006 | 18 |
| NCT00471965Carcinoma, Hepatocellular · China, Korea, Republic of, Taiwan and more | 3 | Completed | Sanofi | Mar 2010 | 371 |
| NCT00439426Nasopharyngeal Neoplasms · Morocco | 2 | Completed | Hoffmann-La Roche | Sep 2009 | 25 |
| NCT00436800Nasopharyngeal Neoplasms · Hong Kong | 2 | Completed | Sanofi | Oct 2008 | 41 |
| NCT00436241Stomach Neoplasms · Taiwan | 2 | Completed | Hoffmann-La Roche | Nov 2010 | 45 |
| NCT00421824Rectal Neoplasms · Spain | 2 | Completed | Sanofi | Nov 2010 | 108 |
| NCT00411229Stomach Neoplasms · China, Korea, Republic of, Taiwan | 3 | Completed | Sanofi | Nov 2012 | 1,035 |
| NCT00403624Rectal Neoplasms | 2 | Completed | Sanofi | Nov 2005 | 38 |
| NCT00399750Colorectal Neoplasms · United States | 2 | Completed | Sanofi | 373 | |
| NCT00382720Stomach Neoplasms · United States, Belgium, France and more | 2 | Completed | Sanofi | Apr 2010 | 275 |
| NCT00356122Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Sanofi | Aug 2010 | 53 |
| NCT00353262Colorectal Neoplasms · Canada | 1 | Completed | Hoffmann-La Roche | Sep 2006 | 36 |
| NCT00345761Colorectal Neoplasms · Japan | 2 | Completed | Hoffmann-La Roche | Oct 2008 | 64 |
| NCT00296816Ovarian Neoplasms · United States | 2 | Completed | Sanofi | Aug 2011 | 132 |
| NCT00280618Carcinoma, Hepatocellular | 2 | Completed | Sanofi | Nov 2006 | |
| NCT00275210Colonic Neoplasms · Australia, Austria, Belgium and more | 3 | Completed | Sanofi | Apr 2003 | 2,246 |
| NCT00271271Carcinoma, Non-Small-Cell Lung · France | 2 | Completed | Sanofi | 40 | |
| NCT00263354Stomach Neoplasms | 2 | Completed | Sanofi | Jul 2006 | 20 |
| NCT00263055Colonic Neoplasms · China, Hong Kong, Korea, Republic of and more | 4 | Completed | Sanofi | Jun 2005 | |
| NCT00263029Rectal Neoplasms | 2 | Completed | Sanofi | Mar 2007 | 18 |
| NCT00261092Pancreatic Neoplasms · Korea, Republic of | 2 | Completed | Sanofi | 48 | |
| NCT00259363Rectal Neoplasms · Spain | 2 | Terminated | Sanofi | Jun 2006 | 46 |
| NCT00174616Rectal Neoplasms · Belgium, France, Germany and more | 2 | Completed | Sanofi | Nov 2007 | 87 |
| NCT00174564Biliary Tract Neoplasms | 2 | Completed | Sanofi | Sep 2006 | 67 |
| NCT00129870Colorectal Neoplasms · United States | 4 | Terminated | Sanofi | 180 | |
| NCT00094965Gastrointestinal Neoplasms · United States | 2 | Completed | Sanofi | Aug 2007 | 43 |
| NCT00069121Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Apr 21, 2011 | 1,886 |
How it is read
Names in the registry
- “Oxaliplatin”, 51 entries
- “oxaliplatin”, 20 entries
- “Oxaliplatin (SR96669)”, 3 entries
- “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
- “OXALIPLATIN”, 3 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 35 studies
- Stomach Neoplasms, 16 studies
- Pancreatic Neoplasms, 7 studies
- Rectal Neoplasms, 6 studies
- Carcinoma, Hepatocellular, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.